Skip to main content

The use of Cytomegalovirus (CMV) T Cell Immunity Panel to Assess the Risk of Clinically Significant CMV Infection in Recipients of Cellular Therapy with Low Level CMV Viremia

Learn about an ongoing study which Dr. Chemaly and his team at MD Anderson have utilized CMV inSIGHT™ T Cell Immunity testing to:
  • Identify cellular therapy recipients (both on and off letermovir for prophylaxis) who are high risk for clinically significant CMV infection.
  • Assess the benefit of early treatment of low level CMV viremia who are not on letermovir prophylaxis and high risk for clinically significant CMV infection
  • Determine utility of the CMV inSIGHT™ T Cell Immunity test in the management of low level CMV viremia in high and low risk patient populations on letermovir.

Length of Presentation: 24 minutes

Presented by: 

  • Dr. Roy Chemaly, MD, MPH, FIDSA, FACP
    MD Anderson Cancer Center

Q&A by: 

  • Dr. Fareed Khawaja, MD
    MD Anderson Cancer Center

 

Back to top